By Chad Terhune (Reuters) – Drugs like Wegovy may trim your waistline but not medical costs, according to an analysis...
Read moreThursday’s trading session is showcasing notable movements across the board, with mega-cap stocks like Tesla Motors (NASDAQ:TSLA) and IBM (NYSE:IBM)...
Read moreBy Felix Njini JOHANNESBURG (Reuters) – The speed at which Anglo American (JO:AGLJ) shifts to becoming a copper-focused miner may...
Read moreLONDON (Reuters) – Global commercial insurance rates fell 1% in the third quarter of 2024, the first quarterly decline recorded...
Read moreInvesting.com – Greece stocks were lower after the close on Thursday, as losses in the Telecoms, Household and Basic Resources...
Read moreTesla (NASDAQ:TSLA)’s latest quarterly report sparked a more than 14% rise in the stock premarket Thursday. Following the results, various...
Read moreInvesting.com — Hermes International SCA (EPA:HRMS) posted a sharp increase in third-quarter sales on Thursday, outperforming competitors that have been...
Read moreLONDON – Assura plc, a prominent UK healthcare real estate investment trust (REIT), has concluded the sale of 12 properties,...
Read moreBy Abhijith Ganapavaram and Tim Hepher (Reuters) -Boeing shares fell 4% in U.S. pre-market trading on Thursday after workers voted...
Read more(Reuters) -United Parcel Service surpassed Wall Street estimates for quarterly profit and raised its full-year adjusted operating margin forecast on...
Read moreDisclaimer: WallStreetJedi.com, its managers, its employees, and assigns (collectively "The Company") do not make any guarantee or warranty about what is advertised above. Information provided by this website is for research purposes only and should not be considered as personalized financial advice. The Company is not affiliated with, nor does it receive compensation from, any specific security. The Company is not registered or licensed by any governing body in any jurisdiction to give investing advice or provide investment recommendation. Any investments recommended here should be taken into consideration only after consulting with your investment advisor and after reviewing the prospectus or financial statements of the company.